The Director, HTA, Value & Evidence (HV&E) – Internal Medicine Early Pipeline will support the strategic goals of the Internal Medicine Division by driving optimal patient access for Pfizer’s portfolio of obesity and non-obesity products in early pipeline.

This role influences global business objectives by guiding strategic evidence development to ensure optimal patient access for obesity and non-obesity products. In collaboration with the asset development team, the Director will formulate HEOR strategy and conduct/oversee evidence generation activities, in particular, real-world data (RWD) studies and economic models for cost-effectiveness and budget impact, to support assets in the early pipeline phase and prepare for phase 3. The HV&E Director will be responsible for developing and executing against the global evidence generation strategy, including direct oversight of evidence generation activities and dissemination of technical deliverables.

This position will be part of Pfizer’s dynamic Global HTA Value and Evidence team and will have the important role of managing health economics and outcomes research (HEOR) to generate data to support patient access to obesity and non-obesity products, with a primary focus on obesity products in early clinical development. This position will be working closely with the Primary Care Global Access Strategy and Pricing (GASP) team, US Market Access team, cross-functional and country teams to foster a culture that promotes innovation and thrives on doing better for Pfizer’s patients and society in general.

What You Will Achieve

In this role, you will:

• Provide strategic input into clinical trial designs (e.g., patient populations, comparators, endpoints) and analysis to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.

• Lead the development of the evidence generation strategy to support the value of Internal Medicine assets (focus on obesity and non-obesity products) in the Primary Care Division, in close partnership with the cross-functional matrix team (e.g., medical, commercial, access strategy/pricing, statistics, clinical).

• Lead the coordination of input from local country/regional teams on evidence needs and ensure that the input is appropriately incorporated into the evidence strategy to support global market access needs at launch and through lifecycle.

• Lead the design and execution of global HEOR studies (e.g., network meta-analyses, non-interventional studies, economic models) from concept through publication.  

• Develop patient-reported outcomes strategy and incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence aligned with overall asset strategy and to ensure global reimbursement and access requirements.

• Partner with internal stakeholders to ensure appropriate customer-facing dissemination of HEOR materials per regulatory guidance and internal SOPs

• Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, and various academic and community oncology settings to support asset strategies.

Basic Qualifications:

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

• Graduate degree required (e.g. MSc, MPH, PhD)

• 7+ years of experience with MSc/MPH/MBA degree; 5+ years with PharmD/PhD/DrPH in HEOR or relevant related fields (health economics, epidemiology, health services research, or other research-focused public health field)

• Expertise in HEOR strategy, evidence development, fundamental health services research methods and tools, including health economic modeling, patient-reported outcomes, statistics, and real-world evidence studies including technical and methodological aspects of registries and observational study design, implementation, analysis and interpretation.

• Capable of independently managing complex non-interventional study projects

• Knowledge and understanding of drug development process

• Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers

• Excellent oral and written English communication skills

• Demonstrated ability to assess anticipated value for projects/programs to ensure alignment to business priorities and prioritize accordingly

• An “execution mindset” focused on getting things done quickly and simply

• Strong project management abilities (contracting, budgeting, vendor management) essential. Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities and expertise in stakeholder engagement

• Leadership in cross-functional teams (e.g. influence medical, clinical, and commercial teams constructively and without conflict); strategic thinking, and ability to guide junior team members

• Skilled in functioning within a matrix organization

• Organized and detail oriented with the ability to anticipate needs and to work proactively to prioritize & address/resolve

• Change oriented, comfortable responding to unexpected demands with tight timelines

Bonus Points If You Have (Preferred Requirements):

• Knowledge and experience in obesity / internal medicine space

• Experience with HTA organizations such as NICE, CADTH, PBAC, ICER and other HTA groups

• Previous experience with early-stage development, clinical trials, and patient-reported outcomes.

• world study design and implementation

• Experience with developing early economic models to inform early clinical development and early pricing

• Experience in supporting global obesity / internal medicine launch

• Experience using common AI tools, including generative technologies such as ChatGPT or Microsoft Copilot, to support problem solving and enhance productivity. Demonstrated curiosity for exploring how these tools can improve outcomes and understanding of responsible AI practices, including risk management and ethical use

OTHER JOB DETAILS:

• Last Date to Apply for Job: August 27, 2026

• Ability to travel travel domestically and internationally

• Ability to work in all US time zones

• Location: US any Pfizer site or Europe any Pfizer site

• NOT eligible for Relocation Package

• This position is hybrid and requires working onsite 2 to 3 days per week